control group:Recombinant human erythropoietin: 10000 IU subcutaneous injection once a day

2 trials

Sponsors

The First Affiliated Hospital, College of Medicine, Zhejiang University, The First Affiliated Hospital of Zhejiang University Medical College

Conditions

Myelodysplastic Syndrome

Phase 4

Phase II / III clinical study on the efficacy and safety of recombinant human erythropoietin combined with retinoic acid and testosterone undecanoate in the treatment of anemia in patients with relatively low-risk myelodysplastic syndrome

Active, not recruitingChiCTR2000030594

The First Affiliated Hospital, College of Medicine, Zhejiang UniversityMyelodysplastic Syndrome

Start: 2020-04-01Updated: 2020-03-09

Prospective, open-label, multicenter clinical study on the efficacy and safety of recombinant human erythropoietin combined with retinoic acid and testosterone undecanoate in the treatment of anemia in patients with low-risk myelodysplastic syndrome

Active, not recruitingChiCTR2000032845

The First Affiliated Hospital of Zhejiang University Medical CollegeMyelodysplastic Syndrome

Start: 2020-05-06Updated: 2020-06-08

Related Papers

Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial

Haematologica2025-06-121 citations